ArticlePloS one2017
Chlamydia trachomatis Pgp3 Antibody Population Seroprevalence before and during an Era of Widespread Opportunistic Chlamydia Screening in England (1994-2012).
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Preconception Chlamydia trachomatis seropositivity and fecundability, live birth, and adverse pregnancy outcomes.Fertility and sterility · 2025Trial
- UnveilingiScience · 2025Article
- Comparison of Chlamydia trachomatis Seroprevalence and Risk Factors for Infection Among Women by Gender/Sex of Sex Partner, United States, 2013-2016.Sexually transmitted diseases · 2025Article
- Current Evidence of Maternal Infection With Chlamydia trachomatis and Preeclampsia Risk.American journal of reproductive immunology (New York, N.Y. : 1989) · 2025Review
- Cross-sectional study on the seroprevalence, reinfection, and associated factors of Chlamydia trachomatis among female sex workers in Guangdong Province, China.BMC infectious diseases · 2025Article
- Prevalence and risk factors for Chlamydia trachomatis seropositivity and seropersistence among women: A prospective cohort study.PloS one · 2025Article
- Chlamydia trachomatis Seroassays Used in Epidemiologic Research: A Narrative Review and Practical Considerations.The Journal of infectious diseases · 2024Review
- Trends inSexually transmitted infections · 2024Article
- The serodiagnositic value ofFrontiers in public health · 2024Article
- Using infection prevalence, seroprevalence and case report data to estimate chlamydial infection incidence.Sexually transmitted infections · 2023Article
- Review
- Plasmid-mediated virulence inFrontiers in cellular and infection microbiology · 2023Review
- Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank.Nature communications · 2022Article
- Seroprevalence of Chlamydia trachomatis Among Female Adults in the United States: The National Health and Nutrition Examination Surveys.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Molecular Epidemiology of Human Papillomaviruses,Tropical medicine and infectious disease · 2021Article
- Seroepidemiology ofFrontiers in microbiology · 2021Article
- Article
- Multi-peptide ELISAs overcome cross-reactivity and inadequate sensitivity of conventional Chlamydia pneumoniae serology.Scientific reports · 2019Article
- Antibody Testing in Estimating Past Exposure to CMicroorganisms · 2019Article
- Relation betweenSexually transmitted infections · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOpportunistic chlamydia screening of <25 year-olds was nationally-implemented in England in 2008 but its impact on chlamydia transmission is poorly understood. We undertook a population-based seroprevalence study to explore the impact of screening on cumulative incidence of chlamydia, as measured by C.trachomatis-specific antibody.
methodsAnonymised sera from participants in the nationally-representative Health Surveys for England (HSE) were tested for C.trachomatis antibodies using two novel Pgp3 enzyme-linked immunosorbent assays (ELISAs) as a marker of past infection. Determinants of being seropositive were explored using logistic regression among 16-44 year-old women and men in 2010 and 2012 (years when sexual behaviour questions were included in the survey) (n = 1,402 women; 1,119 men). Seroprevalence trends among 16-24 year-old women (n = 3,361) were investigated over ten time points from 1994-2012.
resultsIn HSE2010/2012, Pgp3 seroprevalence among 16-44 year-olds was 24.4% (95%CI 22.0-27.1) in women and 13.9% (11.8-16.2) in men. Seroprevalence increased with age (up to 33.5% [27.5-40.2] in 30-34 year-old women, 18.7% [13.4-25.6] in 35-39 year-old men); years since first sex; number of lifetime sexual partners; and younger age at first sex. 76.7% of seropositive 16-24 year-olds had never been diagnosed with chlamydia. Among 16-24 year-old women, a non-significant decline in seroprevalence was observed from 2008-2012 (prevalence ratio per year: 0.94 [0.84-1.05]).
conclusionOur application of Pgp3 ELISAs demonstrates a high lifetime risk of chlamydia infection among women and a large proportion of undiagnosed infections. A decrease in age-specific cumulative incidence following national implementation of opportunistic chlamydia screening has not yet been demonstrated. We propose these assays be used to assess impact of chlamydia control programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.